摘要
目的比较脂质体紫杉醇联合顺铂与吉西他滨联合顺铂一线治疗非小细胞肺癌肝转移的效果和安全性。方法将95例初治晚期非小细胞肺癌肝转移患者随机分2组,分别给予脂质体紫杉醇+顺铂(观察组)、吉西他滨+顺铂(对照组)。比较2组的疗效和不良反应。结果肺原发灶疗效比较,2组客观有效率、疾病控制率差异无统计学意义(P>0.05)。肝转移灶疗效比较,观察组客观有效率高于对照组,差异有统计学意义(P<0.05),但2组疾病控制率差异无统计学意义(P>0.05)。2组无进展生存期差异无统计学意义(P>0.05)。2组均未出现治疗相关性死亡,观察组胃肠道毒性、血小板减少发生率明显低于对照组(P<0.05)。结论脂质体紫杉醇与吉西他滨一线治疗晚期非小细胞肺癌肝转移患者的效果相当,但脂质体紫杉醇化疗方案可能更有利于控制肝脏转移灶,且胃肠道毒性、血小板减少发生率明显低于吉西他滨化疗方案,更能使患者获益。
Objective To compare the efficacy and safety between paclitaxel liposome and gemcitabine respectively combined with cisplatin as a first line treatment for non-small cell lung cancer with hepatic metastases.Methods A total of 95 patients were randomly assigned to receive either paclitaxel liposome or gemcitabine respectively combined with cisplatin.Efficacy and safety between two group were compared.Results There was no significant difference in lung cancer of objective response rate,disease control rate,progression-free survival between two groups.But objective response rate was higher in paclitaxel liposome group about hepatic metastases.There was no treatment-related death among two groups.Paclitaxel liposome was associated with less thrombocytopenia and gastrointesting toxicity.Conclusion Paclitaxel liposome has the same efficacy with gemcitabine,and less adverse reactions.Also paclitaxel liposome maybe more helpful to control hepatic metastases.
作者
刘颖
王泽阳
任文君
刘丽华
侯志华
刘欣燕
LIU Ying;WANG Ze-yang;REN Wen-jun;LIU Li-hua;HOU Zhi-hua;LIU Xin-yan(Department of Oncology,Hehei Chest Hospital,Shijiazhuang 050041,China;Department of Oncology,Hebei General Hospital,Shijiazhuang 050051,China)
出处
《河北医科大学学报》
CAS
2018年第7期810-812,821,共4页
Journal of Hebei Medical University
关键词
肺肿瘤
肝转移
脂质体紫杉醇
吉西他滨
lung neoplasms
hepatic metastases
paclitaxel liposome
gemcitabine
